• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

       

      ONE REGIMEN,

      ALL GENOTYPES, 8 WEEKS1

      8-week treatment for GT 1-6, treatment-naïve,
      cirrhotic and non-cirrhotic HCV patients.1

      Three tablets
      once-daily
      with food1

      No baseline
      resistance or viral
      load testing needed1

      No ribavirin
      required in any
      patients1

       

      Maviret indication1

      Maviret is indicated for the treatment of chronic hepatitis C virus (HCV) infection, genotypes 1-6, in adults and in adolescents aged 12 to <18 years with compensated liver disease. Maviret may be used for a minimum of 12 weeks in liver and kidney transplant recipients - see SmPC for specific genotypes.

      *Cure = sustained virologic response (SVR12), defined as HCV RNA less than lower limit of quantification at 12 weeks after the end of treatment and was the primary endpoint in all the studies.1

      References

      1. Maviret Summary of Product Characteristics. AbbVie Ltd. Available at: www.medicines.org.uk
      2. Harvoni Summary of Product Characteristics. Gilead Sciences Ltd. Available at: www.medicines.org.uk (accessed December 2020).
      3. Epclusa Summary of Product Characteristics. Gilead Sciences Ltd. Available at: www.medicines.org.uk (accessed December 2020).
      4. Vosevi Summary of Product Characteristics. Gilead Sciences Ltd. Available at: www.medicines.org.uk (accessed December 2020).
      5. Zepatier Summary of Product Characteristics. Merck Sharp & Dohme Ltd. Available at: www.medicines.org.uk (accessed December 2020).
       

       

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk .
      Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      UK-MAVI-200065. Date of preparation: December 2020